AI Insight
A phase 3 clinical trial (HARMONi-2) found that ivonescimab significantly extended overall survival compared to pembrolizumab when used as first-line treatment in patients with PD-L1-positive advanced non-small cell lung cancer. These results come from a prespecified interim analysis presented at the IASLC 2026 World Conference on Lung Cancer. The findings suggest ivonescimab may offer superior efficacy over the current standard immunotherapy treatment for this patient population.
Why it matters
This could represent a meaningful advancement in treating advanced lung cancer, potentially offering patients with PD-L1-positive NSCLC a more effective first-line treatment option than pembrolizumab, which is currently a widely used standard of care. If confirmed in final analysis, this could change clinical practice guidelines for lung cancer treatment.
Understand the Science
Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.
Source: Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer